Skip to product information
1 of 1

FDA ANDA 218281, ERIBULIN MESYLATE, JIANGXI QINGFENG, 06/28/2024

FDA ANDA 218281, ERIBULIN MESYLATE, JIANGXI QINGFENG, 06/28/2024

Regular price $203.95 USD
Regular price Sale price $203.95 USD
Sale Sold out

Contents: Approval Letter and the Summary Basis of Approval of CMC (Chemistry, Manufacture and Control) section for ERIBULIN MESYLATE 1MG/2ML (0.5mg/mL) ANDAs A218281 and A214850 approved on Jun 18, 2024 and July 18, 2024 respectively

ANDA: 218281
Company: JIANGXI QINGFENG
Drug Name: ERIBULIN MESYLATE
Active Ingredients: ERIBULIN MESYLATE
Strength: 1MG/2ML (0.5MG/ML)
Dosage Form/Route: SOLUTION;INTRAVENOUS
Action Date: 06/28/2024
Marketing Status: Prescription
Submission Classification: ORIG-1

45 Pages 

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome